GALAFOLD
Total Payments
$1.8M
Transactions
1,598
Doctors
397
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $327,391 | 242 | 26 |
| 2023 | $195,877 | 183 | 91 |
| 2022 | $180,205 | 127 | 95 |
| 2021 | $190,022 | 406 | 84 |
| 2020 | $455,393 | 203 | 82 |
| 2019 | $407,890 | 437 | 162 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 820 | 80.8% |
| Consulting Fee | $173,163 | 77 | 9.9% |
| Travel and Lodging | $147,264 | 67 | 8.4% |
| Food and Beverage | $17,233 | 632 | 1.0% |
| Education | $81.60 | 2 | 0.0% |
Payments by Type
Research
$1.4M
820 transactions
General
$337,741
778 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) | Amicus Therapeutics, Inc. | $674,651 | 0 |
| Developing a management approach for patients with the "late-onset" Pompe disease GAA variant identified by newborn screening: Towards better development and health | Amicus Therapeutics, Inc. | $183,794 | 0 |
| Tunneling Nanotube Associated Cross-Correction of Fabry cells in an In-vitro Model of Fabry Podocytopathy in Females. | Amicus Therapeutics, Inc. | $152,696 | 0 |
| A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease | Amicus Therapeutics, Inc. | $119,427 | 0 |
| Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease | Amicus Therapeutics, Inc. | $100,590 | 0 |
| Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease | Amicus Therapeutics, Inc. | $96,308 | 0 |
| Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease | Amicus Therapeutics, Inc. | $41,842 | 0 |
| A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Amicus Therapeutics, Inc. | $28,119 | 0 |
| A Retrospective Characterization of Patients with Amenable GLA Variants Being Treated for Fabry Disease | Amicus Therapeutics, Inc. | $11,600 | 0 |
| A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA) | Amicus Therapeutics, Inc. | $10,012 | 0 |
Top Doctors Receiving Payments for GALAFOLD
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $1.4M | 820 |
| , M.D | Clinical Genetics (M.D.) | Cincinnati, OH | $64,669 | 38 |
| , DO | Clinical Biochemical Genetics | Philadelphia, PA | $50,786 | 26 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Dallas, TX | $48,885 | 24 |
| , M.D | Pediatric Cardiology | Memphis, TN | $20,651 | 21 |
| , MD | Nephrology | Birmingham, AL | $17,985 | 11 |
| , MD | Anatomic Pathology | Seattle, WA | $15,085 | 7 |
| , GNP-BC | Gerontology | San Antonio, TX | $12,611 | 4 |
| Stephanie Dearmey | Pediatrics | Durham, NC | $11,998 | 5 |
| , M.D | Clinical Genetics (M.D.) | Pittsburgh, PA | $11,775 | 4 |
| Priya Kishnani | Pediatrics | Durham, NC | $11,530 | 5 |
| , MD | Neurodevelopmental Disabilities | Dallas, TX | $11,267 | 4 |
| , MD | Clinical Genetics (M.D.) | Minneapolis, MN | $11,008 | 8 |
| , M.D | Internal Medicine | Boston, MA | $4,800 | 2 |
| , M.D., M.P.H | Nephrology | Fort Worth, TX | $4,277 | 6 |
| , M.D | Neurology with Special Qualifications in Child Neurology | New York, NY | $4,043 | 3 |
| , M.D | Neuromuscular Medicine | Aurora, CO | $3,000 | 1 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $3,000 | 1 |
| , M.D | Nephrology | Kansas City, KS | $2,750 | 1 |
| , MD | Neurology | Orange, CA | $2,224 | 1 |
| , MD | Nephrology | Los Angeles, CA | $2,088 | 10 |
| , MD | Cardiovascular Disease | Burlington, MA | $1,824 | 1 |
| , MD | Pediatric Cardiology | Gainesville, FL | $1,692 | 4 |
| , M.D., PH.D | Clinical Genetics (M.D.) | Gainesville, FL | $1,665 | 2 |
| , M.D., PH.D | Clinical Genetics (M.D.) | Washington, DC | $1,348 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 397
- Transactions 1,598
About GALAFOLD
GALAFOLD is a drug associated with $1.8M in payments to 397 healthcare providers, recorded across 1,598 transactions in the CMS Open Payments database. The primary manufacturer is Amicus Therapeutics, Inc..
Payment data is available from 2019 to 2024. In 2024, $327,391 was paid across 242 transactions to 26 doctors.
The most common payment nature for GALAFOLD is "Unspecified" ($1.4M, 80.8% of total).
GALAFOLD is associated with 10 research studies, including "Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)" ($674,651).